Zacks Investment Research announced Cryolife Inc (NYSE:CRY), bumping up its stock price target to $19.00 today
- Updated: October 17, 2016
In a report released on 10/17/2016 Zacks Investment Research increased the stock price target of Cryolife Inc (NYSE:CRY) to $19.00 reporting a possible upside of 0.13%.
Just yesterday Cryolife Inc (NYSE:CRY) traded -0.36% lower at $16.81. Cryolife Inc’s 50-day moving average is $17.29 and its 200-day moving average is $13.75. The last stock price is up 21.78% from the 200-day moving average, compared to the Standard & Poor's 500 Index which has decreased -0.01% over the same time period. 149,879 shares of CRY traded hands, down from an average trading volume of 302,682
Recent Performance Chart
Cryolife Inc has 52 week low of $8.94 and a 52 week high of $18.64 with a PE ratio of 53.69 and has a market capitalization of $0.
In addition to Zacks Investment Research reporting its stock price target, a total of 4 brokerages have issued a research note on the company. The average stock price target is $13.75 with 3 brokerages rating the stock a strong buy, 0 brokerages rating the stock a buy, 0 brokerages rating the stock a hold, 0 brokerages rating the stock a underperform, and finally 0 brokerages rating the stock a sell.
Brief Synopsis On Cryolife Inc (NYSE:CRY)
CryoLife, Inc. (CryoLife) is engaged in medical device manufacturing and distribution, and in the processing and distribution of implantable human tissues for cardiac and vascular surgeries. The Company operates in two segments: Medical Devices and Preservation Services. The Medical Devices segment sells BioGlue, BioFoam, PerClot, CardioGenesis cardiac laser therapy, Hemodialysis Reliable Outflow (HeRO) Graft, and ProCol Vascular Bioprosthesis (ProCol). The Preservation Services segment preserves cardiac and vascular tissues. The Company's surgical sealants and hemostats include BioGlue Surgical Adhesive (BioGlue), BioFoam Surgical Matrix (BioFoam), and PerClot, an absorbable powdered hemostat, which the Company distributes internationally for Starch Medical, Inc. (SMI). Its CardioGenesis cardiac laser therapy product line includes a laser console system and single-use, fiber-optic handpieces.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.